Our Latest News
Tuesday January 10, 2023
Happy 2023! May it be a happy, healthy year for you and yours. We’ve done a quick roundup of 2022 in our latest newsletter – have a read here. We’ve got so many exciting things in store for 2023 – consider signing up to our mailing list here to keep up to date!
Friday October 14, 2022
We’re delighted to announce our shift in focus to rare disease! Many people living with a rare disease and their families struggle with significant unmet medical needs, and few have the opportunity to be involved in research. Given that over 70% of our feasible proposals have come from small rare disease groups, we’ve decided to […]
Tuesday October 11, 2022
Time for us to announce our shift to rare disease! Over 70% of our proposals come from small rare disease patient groups or charities, so we’ve decided to focus on this under-served community. We look forward to working with the Cambridge Rare Disease Network, Beacon for Rare Diseases, and many others to learn how we […]
Monday August 22, 2022
Are you or someone you care for affected by Neurofibromatosis Type 1 (NF1)? Do you provide healthcare for someone with NF1? We’re helping Childhood Tumour Trust learn more about the current pathway of care for people with NF1 in the UK. If you’re involved in either receiving or providing care, please consider completing our surveys. […]
Monday July 25, 2022
PKD Charity and the autosomal dominant polycystic kidney disease (ADPKD) community paired up with NIHR’s James Lind Alliance on a Priority Setting Partnership (PSP). They’ve agreed their Top 10 research priorities, and have published it in BMJ Open! Have a read here. We’re pleased to have supported PKD Charity with two relevant patient-led projects; hopefully […]
Monday July 4, 2022
Newsletter time! It’s been a really busy quarter for us: lots of proposal work, but also lots of behind-the-scenes development work. We look forward to sharing all with you as soon as possible! Read what we’ve been up to here, and consider joining our mailing list here.